Skip to main content
TipRanks
Go Ultimate75% OFF

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

NKTR Analyst Ratings

Moderate Buy
14Ratings
10Buy4Hold0Sell
Based on 14 analysts giving stock ratings to Nektar Therapeutics in the past 3 months

NKTR Stock 12 Month Forecast

CHF110.86▲(0.00% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is CHF 110.86 with a high forecast of CHF 161.35 and a low forecast of CHF 33.61. The average price target represents a ― change from the last price of ―.
Highest Price TargetCHF161.35Average Price TargetCHF110.86Lowest Price TargetCHF33.61

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:NKTR
Price TargetArticle
H.C. WainwrightCHF155.47buy―Reiterated11/16/26
Canaccord GenuityCHF128.57→CHF125.21buy―Reiterated11/16/26
Oppenheimer Analyst forecast on CH:NKTRUnknown AnalystNot RankedOppenheimerCHF117.65buy―Reiterated11/13/26
Piper SandlerCHF161.35buy―Reiterated11/13/26
WedbushCHF42.02→CHF33.61hold―Reiterated11/13/26
Leerink PartnersCHF109.25buy―Reiterated11/13/26
UBSCHF44.54hold―Initiated10/11/26
BTIGCHF149.58buy―Reiterated10/09/26
Raymond James―hold―Initiated10/08/26
CitiCHF126.89buy―Reiterated10/05/26
B. Riley Securities Analyst forecast on CH:NKTRUnknown AnalystNot RankedB. Riley SecuritiesCHF126.05buy―Reiterated10/02/26
William Blair―buy―Reiterated10/01/26
JefferiesCHF126.05buy―Reiterated10/01/26
J.P. MorganCHF54.62hold―Initiated08/21/26
TD Cowen―buy―Reiterated08/13/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PALIPalisade Bio
RZLTRezolute
MDWDMediwound
OVIDOvid Therapeutics
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

3 Months
Arthur He CFA
Arthur He CFAH.C. Wainwright
Success Rate8/20 ratings generated profit
40%
Average Return
+26.38%

Copying Arthur He CFA's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +26.38% per trade.

1 Year
Yasmeen Rahimi
Yasmeen RahimiPiper Sandler
Success Rate8/16 ratings generated profit
50%
Average Return
+143.14%

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +143.14% per trade.

2 Years
Yasmeen Rahimi
Yasmeen RahimiPiper Sandler
Success Rate8/16 ratings generated profit
50%
Average Return
+48.20%

Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +48.20% per trade.

NKTR Analyst Recommendation Trends

010203040Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for NKTR
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy911151816
Buy22231
Hold12354
Sell00000
Strong Sell00000
total1215202621

In the current month, NKTR has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 110.86.

NKTR Financial Forecast

CHF-4CHF-3.25CHF-2.5CHF-1.75CHF-1Q1 2026Q3 2026Q4 2026
HighCHF-1.43
ConsensusCHF-2.07
LowCHF-2.94

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -CHF 2.07 with a range of -CHF 2.94 to -CHF 1.43. The previous quarter’s EPS was -CHF 1.37. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF6.4MCHF9.4MCHF12.4MCHF15.3MCHF18.3MQ1 2026Q3 2026Q4 2026
HighCHF10.1M
ConsensusCHF7.75M
LowCHF6.39M

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is CHF 7.75M with a range of CHF 6.39M to CHF 10.09M. The previous quarter’s sales results were CHF 7.89M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

NKTR Stock Forecast FAQ

What is CH:NKTR’s average 12-month price target, according to analysts?
Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is CHF110.86.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Nektar Therapeutics a Buy, Sell or Hold?
Nektar Therapeutics has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 4 hold ratings and 0 sell ratings.
What is Nektar Therapeutics’s share price target?
The average share price target for Nektar Therapeutics is CHF110.86. This is based on 14 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF161.35, and the lowest forecast is CHF33.61. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Nektar Therapeutics?
Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of Nektar Therapeutics?
To buy shares of CH:NKTR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.